Azitra Reports Q3 2025 Results, Raises $2.8mln Through Equity Line of Credit.

Wednesday, Nov 12, 2025 5:05 pm ET1min read

• Azitra reports Q3 2025 financial results • Dosed first patient in Phase 1/2 trial for ATR-04 program • Presented positive preclinical data for ATR-01 program • Raised $2.8M through equity line of credit with Alumni Capital LP

Comments



Add a public comment...
No comments

No comments yet